NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Forecast & News

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) released its quarterly earnings results on Monday, November, 25th. The biotechnology company reported $0.11 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.14 by $0.03. The biotechnology company earned $43.29 million during the quarter, compared to analyst estimates of $36.97 million. Arrowhead Pharmaceuticals had a net margin of 40.27% and a return on equity of 32.30%. View Arrowhead Pharmaceuticals' Earnings History.

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals will be holding an earnings conference call on Wednesday, February 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

9 equities research analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' stock. Their forecasts range from $32.00 to $83.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $61.14 in the next year. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arrowhead Pharmaceuticals.

Headlines about ARWR stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 11,120,000 shares, a decline of 8.9% from the December 15th total of 12,200,000 shares. Based on an average daily trading volume, of 2,260,000 shares, the days-to-cover ratio is presently 4.9 days. Approximately 11.9% of the company's shares are short sold. View Arrowhead Pharmaceuticals' Current Options Chain.

Some companies that are related to Arrowhead Pharmaceuticals include UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Catalent (CTLT) and Sarepta Therapeutics (SRPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), salesforce.com (CRM), Paypal (PYPL) and Bank of America (BAC).

Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include New York State Teachers Retirement System (0.13%), Columbus Circle Investors (0.06%), Strs Ohio (0.03%), State of Michigan Retirement System (0.03%), Louisiana State Employees Retirement System (0.03%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, New York State Teachers Retirement System, Louisiana State Employees Retirement System, Strs Ohio, Calamos Advisors LLC and IFP Advisors Inc. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry and Patrick O'brien. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

ARWR stock was purchased by a variety of institutional investors in the last quarter, including Columbus Circle Investors, State of Michigan Retirement System, Nisa Investment Advisors LLC, Assenagon Asset Management S.A., Means Investment CO. Inc., Wedbush Securities Inc., NEXT Financial Group Inc and Global Retirement Partners LLC. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $44.61.

Arrowhead Pharmaceuticals has a market capitalization of $4.27 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]